-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Drops By 89.4%
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Drops By 89.4%
PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 500 shares, a drop of 89.4% from the August 15th total of 4,700 shares. Based on an average trading volume of 3,700 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Trading of PureTech Health
An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. grew its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after buying an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. 2.32% of the stock is currently owned by hedge funds and other institutional investors.
Get PureTech Health alerts:PureTech Health Price Performance
NASDAQ PRTC traded up $0.24 during mid-day trading on Thursday, reaching $29.29. 200 shares of the company's stock traded hands, compared to its average volume of 1,478. The company has a fifty day simple moving average of $27.09 and a 200-day simple moving average of $25.12. PureTech Health has a 1-year low of $18.15 and a 1-year high of $54.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.54 and a quick ratio of 2.22.
Wall Street Analyst Weigh In
PRTC has been the topic of a number of recent research reports. Piper Sandler boosted their target price on shares of PureTech Health from $37.00 to $44.00 and gave the stock an "overweight" rating in a research report on Thursday, August 25th. SVB Leerink cut their price objective on shares of PureTech Health from $70.00 to $66.00 and set an "outperform" rating on the stock in a report on Wednesday, June 15th.PureTech Health Company Profile
(Get Rating)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
Featured Articles
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 500 shares, a drop of 89.4% from the August 15th total of 4,700 shares. Based on an average trading volume of 3,700 shares, the days-to-cover ratio is currently 0.1 days.
PureTech Health Plc(纳斯达克代码:prtc-Get Rating)8月份空头股数股价大幅下跌。截至8月31日,空头股数共有500股,与8月15日的4700股相比,下降了89.4%。以3,700股的平均成交量计算,目前天数与回补比率为0.1天。
Institutional Trading of PureTech Health
PureTech Health的制度性交易
An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. grew its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after buying an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. 2.32% of the stock is currently owned by hedge funds and other institutional investors.
一家机构投资者最近提高了对PureTech Health股票的头寸。根据AWM Investment Company Inc.在提交给美国证券交易委员会的最新13F文件中的数据,第二季度该公司在PureTech Health Plc(纳斯达克代码:PRTC-GET评级)的股票持仓增加了2,100.0%。该基金持有66万股该公司股票,在此期间又购买了63万股。截至最近提交的美国证券交易委员会申请文件,AWM Investment Company Inc.持有PureTech Health约2.32%的股份,价值2,513,000美元。2.32%的股票目前由对冲基金和其他机构投资者持有。
PureTech Health Price Performance
PureTech健康性价比
NASDAQ PRTC traded up $0.24 during mid-day trading on Thursday, reaching $29.29. 200 shares of the company's stock traded hands, compared to its average volume of 1,478. The company has a fifty day simple moving average of $27.09 and a 200-day simple moving average of $25.12. PureTech Health has a 1-year low of $18.15 and a 1-year high of $54.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.54 and a quick ratio of 2.22.
纳斯达克商城周四午盘交易中上涨0.24美元,至29.29美元。该公司有200股股票易手,而其平均成交量为1,478股。该公司的50日简单移动均线切入位为27.09美元,200日简单移动均线切入位为25.12美元。PureTech Health的一年低点为18.15美元,一年高位为54.39美元。该公司的债务权益比为0.02,流动比率为2.54,速动比率为2.22。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
PureTech Health Company Profile
PureTech Health公司简介
(Get Rating)
(获取评级)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
PureTech Health plc是一家临床阶段的生物治疗公司,在美国发现、开发和销售治疗炎症、纤维化和免疫、顽固性癌症、淋巴和胃肠道、神经和神经心理以及其他疾病的药物。该公司提供靶向M胆碱乙酰胆碱受体的KarXT,用于治疗阿尔茨海默病的精神分裂症和精神病;用于治疗雄激素性脱发、上皮老化和其他疾病的再生生物学平台;用于治疗慢性和急性炎症性疾病的免疫调节平台;用于从人体微生物群中分离出基于特定细菌群的口服疗法;以及用于治疗与抑郁症、多发性硬化症、COVID后和ICU以及癌症相关疾病相关的认知功能障碍的疗法。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
- 免费获取StockNews.com关于PureTech Health(PRTC)的研究报告
- 为什么医疗产品制造商Repligen可能成为潜在收购对象
- 在10%的水平上,Arbor Realty Trust的股息值得吗?
- 投资者应关注RF Industries
- Netflix可能刚刚触底的两个原因
- 3M已经到了坏到好的地步了吗?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
获得PureTech HealthDaily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对PureTech Health和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧